Engineered immune cells take on stubborn arthritis in early trial
Disease control
Recruiting now
This early-phase study tests a new treatment called ADI-001 for adults with rheumatoid arthritis that hasn't improved with standard therapies. ADI-001 uses specially engineered immune cells from a donor to target and destroy faulty immune cells that drive inflammation. The main g…
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC